» Articles » PMID: 23844272

Targeting Microglial K(ATP) Channels to Treat Neurodegenerative Diseases: a Mitochondrial Issue

Overview
Publisher Wiley
Date 2013 Jul 12
PMID 23844272
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Neurodegeneration is a complex process involving different cell types and neurotransmitters. A common characteristic of neurodegenerative disorders is the occurrence of a neuroinflammatory reaction in which cellular processes involving glial cells, mainly microglia and astrocytes, are activated in response to neuronal death. Microglia do not constitute a unique cell population but rather present a range of phenotypes closely related to the evolution of neurodegeneration. In a dynamic equilibrium with the lesion microenvironment, microglia phenotypes cover from a proinflammatory activation state to a neurotrophic one directly involved in cell repair and extracellular matrix remodeling. At each moment, the microglial phenotype is likely to depend on the diversity of signals from the environment and of its response capacity. As a consequence, microglia present a high energy demand, for which the mitochondria activity determines the microglia participation in the neurodegenerative process. As such, modulation of microglia activity by controlling microglia mitochondrial activity constitutes an innovative approach to interfere in the neurodegenerative process. In this review, we discuss the mitochondrial KATP channel as a new target to control microglia activity, avoid its toxic phenotype, and facilitate a positive disease outcome.

Citing Articles

Timed sulfonylurea modulation improves locomotor and sensory dysfunction following spinal cord injury.

Xu G, Maskey M, Wu Z, Yang Q Front Pharmacol. 2024; 15:1440198.

PMID: 39148545 PMC: 11324438. DOI: 10.3389/fphar.2024.1440198.


Glial metabolic alterations during glaucoma pathogenesis.

Rombaut A, Brautaset R, Williams P, Tribble J Front Ophthalmol (Lausanne). 2024; 3:1290465.

PMID: 38983068 PMC: 11182098. DOI: 10.3389/fopht.2023.1290465.


The impact of ATP-sensitive potassium channel modulation on mitochondria in a Parkinson's disease model using SH-SY5Y cells depends on their differentiation state.

Evinova A, Baranovicova E, Hajduchova D, Dibdiakova K, Baranova I, Racay P J Bioenerg Biomembr. 2024; 56(4):347-360.

PMID: 38689156 PMC: 11217133. DOI: 10.1007/s10863-024-10018-x.


The Anti-diabetic Drug Gliquidone Modulates Lipopolysaccharide-Mediated Microglial Neuroinflammatory Responses by Inhibiting the NLRP3 Inflammasome.

Kim J, Park J, Shah K, Mitchell S, Cho K, Hoe H Front Aging Neurosci. 2021; 13:754123.

PMID: 34776934 PMC: 8587901. DOI: 10.3389/fnagi.2021.754123.


Naloxone Protects against Lipopolysaccharide-Induced Neuroinflammation and Microglial Activation via Inhibiting ATP-Sensitive Potassium Channel.

Tang Z, Shao X, Wu J, Chen H, Zhang A, Xu F Comput Math Methods Med. 2021; 2021:7731528.

PMID: 34373698 PMC: 8349287. DOI: 10.1155/2021/7731528.


References
1.
Henkel J, Beers D, Zhao W, Appel S . Microglia in ALS: the good, the bad, and the resting. J Neuroimmune Pharmacol. 2009; 4(4):389-98. DOI: 10.1007/s11481-009-9171-5. View

2.
Peart J, Gross G . Sarcolemmal and mitochondrial K(ATP) channels and myocardial ischemic preconditioning. J Cell Mol Med. 2003; 6(4):453-64. PMC: 6741323. DOI: 10.1111/j.1582-4934.2002.tb00449.x. View

3.
Chen J, Connor K, Smith L . Overstaying their welcome: defective CX3CR1 microglia eyed in macular degeneration. J Clin Invest. 2007; 117(10):2758-62. PMC: 1994636. DOI: 10.1172/JCI33513. View

4.
Desler C, Rasmussen L . Mitochondria in biology and medicine. Mitochondrion. 2012; 12(4):472-6. DOI: 10.1016/j.mito.2012.06.008. View

5.
Santos D, Cardoso S . Mitochondrial dynamics and neuronal fate in Parkinson's disease. Mitochondrion. 2012; 12(4):428-37. DOI: 10.1016/j.mito.2012.05.002. View